                         SEQUENCE LISTING

<110>  INSERM
 
<120>  METHODS AND KITS FOR DETERMINING WHETHER A CYTOMEGALOVIRUS 
       TRANSPLANTED PATIENT IS AT RISK FOR ALLOGRAFT REJECTION

<130>  BIO12115 GERVOIS/MC

<160>  6     

<170>  PatentIn version 3.3

<210>  1
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  synthetic peptide

<400>  1

Val Met Ala Pro Arg Thr Leu Leu Leu 
1               5                   


<210>  2
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  synthetic peptide

<400>  2

Val Met Ala Pro Arg Thr Leu Val Leu 
1               5                   


<210>  3
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  synthetic peptide

<400>  3

Val Met Ala Pro Arg Thr Leu Ile Leu 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  synthetic peptide

<400>  4

Val Met Ala Pro Arg Thr Leu Val Leu 
1               5                   


<210>  5
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  synthetic peptide

<400>  5

Val Thr Ala Pro Arg Thr Leu Leu Leu 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  synthetic peptide

<400>  6

Val Thr Ala Pro Arg Thr Val Leu Leu 
1               5                   


